致行政开支大增

港股IPO招股书披露先例 · 8 家公司,8 项

此类事项指公司将以股份为基础的付款开支列为期内行政开支大幅增加的主要原因。申请人一般在风险因素、业务、概要及财务资料等章节披露股份支付开支的金额及变动,说明其对行政开支或员工成本的影响,并解释该等开支源于授出购股权或购股奖励、属非现金性质,已在经调整净亏损(非IFRS计量)中剔除或加回,部分申请人预计其占比将随收入增长而下降。

2026-08-30Application Proof
杭州邦顺制药股份有限公司Hangzhou Bangshun Pharmaceutical Co., Ltd.

股份支付开支致行政开支大增

Our administrative expenses amounted to RMB12.2 million, RMB111.2 million, RMB6.2 million and RMB22.7 million in 2024 and 2025 and the six months ended June 30, 2025 and 2026, respectively.

Financial Information · 第 231 页

Our administrative expenses increased during the Track Record Period, primarily due to increases in our share-based payment expenses and [REDACTED] expenses.

Financial Information · 第 231 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-26Application Proof
深圳华大北斗科技股份有限公司Allystar Technology (Shenzhen) Co., Ltd.

股份支付开支逐年增加影响行政费用

Our administrative expenses increased from RMB80.5 million in 2024 to RMB88.1 million in 2025 mainly due to an increase in equity-settled share-based payment expenses and the [REDACTED] expenses.

Business · 第 162 页

Furthermore, our adjusted net loss (a non-IFRS measure) reflects the add-back of the increased expenses incurred during the Track Record Period, including (i) [REDACTED] expenses related to our [REDACTED]; and (ii) equity-settled share-based payment expenses under our share-based arrangement to incentivize our employees.

Summary · 第 8 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-07Application Proof
武汉艾米森生命科技股份有限公司Wuhan Ammunition Life-tech Co., Ltd.

2025年股份支付及上市开支推高行政开支

Our general and administrative expenses amounted to RMB5.8 million, and RMB20.1 million for the years ended December 31, 2024 and 2025, respectively, accounting for 79.7% and 130.0% of our total revenue for the respective periods.

Financial Information · 第 228 页

The increase is mainly attributable to the [REDACTED] expenses and share-based payment expenses incurred in 2025.

Financial Information · 第 228 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-16Application Proof

2025年大额股份支付费用

The increase in 2025 was primarily attributable to higher general and administrative expenses, mainly driven by share-based payment expenses.

Financial Information · 第 174 页

Subtract: Share-based payment expenses | 3.2 | 4.4 | 43.8

Business · 第 142 页

Although our general and administrative expenses as a percentage of revenue were 27.2%, 17.8% and 55.3% in 2023, 2024 and 2025, respectively, our general and administrative expenses (excluding share-based payment expenses) were RMB122.9 million, RMB113.8 million and RMB139.8 million in 2023, 2024 and 2025, respectively.

Business · 第 142 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2025-12-18Prospectus
北京五一视界数字孪生科技股份有限公司Beijing 51WORLD Digital Twin Technology Co., Ltd.06651.HK

股份支付费用对业绩的影响

(ii) the increase in general and administrative expenses of RMB19.9 million primarily due to the increase in share-based payment expenses which were mainly due to the amortization of share options which were granted to Mr. Li Yi under the Pre-IPO share option scheme in the second half of 2024

Business · 第 255 页

Share based payment expenses mainly represent the non-cash employee benefit expenses incurred in connection with our award to our Directors, management and key employees.

Financial Information · 第 299 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2025-07-17Prospectus
南京维立志博生物科技股份有限公司Nanjing Leads Biolabs Co., Ltd.09887.HK

股份支付开支影响行政开支

Share-based compensation represents expenses arising from granting share incentives to senior management and selected employees, which is non-cash in nature.

Summary · 第 20 页

The decrease of our net losses from 2023 to 2024 was primarily due to (i) a decrease of RMB75.2 million in change in fair value of redemption liabilities on equity shares, mainly because we terminated the redemption rights granted to our Pre-IPO Investors pursuant to certain supplemental agreements in 2024, and we no longer recognized any redemption liabilities on equity shares or any loss or gain on fair value changes of such liabilities thereafter; and (ii) a decrease of RMB45.2 million in research and development expenses, mainly attributable to decreases in clinical trial expenses and preclinical and CMC expenses, which aligned with the evolving progress of respective preclinical and clinical programs of our drug candidates; partially offset by an increase of RMB49.6 million in administrative expenses, mainly attributable to an increase in share-based compensation arising from increases in the number and value of share incentives granted, and an increase in professional service fees mainly in connection with the listing expenses incurred.

Summary · 第 22 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2025-04-07Prospectus
映恩生物Duality Biotherapeutics, Inc.09606.HK

股份激励开支推高行政开支

Our administrative expenses increased during the Track Record Period primarily because (i) our business grew and team expanded, (ii) our share incentive expenses increased, and (iii) we engaged professional services in relation to our out-license and collaboration agreements, equity financing and listing.

Financial Information · 第 440 页

The decrease in the percentage of research and development expenses relative to total operating expenses in 2024 was primarily due to increase in administrative expenses caused by share incentive expenses and listing expenses.

Financial Information · 第 440 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2024-09-30Prospectus
七牛智能科技有限公司Qiniu Limited02567.HK

股份支付开支推高行政员工成本

Our staff cost in administrative expenses increased from RMB50.2 million in 2022 to RMB76.3 million in 2023 primarily due to the increase in share-based payments of RMB25.1 million, which is non-cash in nature.

Financial Information · 第 380 页

Share-based payments are non-cash in nature and are employee related expenses arising from grant of share options under our share incentive plan.

Summary · 第 9 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看

Tell us